Pharvaris NV at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Thank you for joining us today and welcome to Pharvaris. I'm Berndt Modig, the CEO of Pharvaris and I'm joined by Morgan Conn, our CBO, Chief Business Officer. Pharvaris' strategy is to fill unmet needs in rare diseases by developing and commercializing therapies that are superior to currently available treatment options and improve patient quality of life and convenience.
Our lead program is in hereditary angioedema or HAE. Currently most standard of care therapies for HAE are administered by injection, which patients can find challenging despite their efficacy because these therapies often result in pain from the injection site reactions. We believe HAE patients want alternatives that better meet their objectives for ease of treatment, disease control and treatments that can match or improve upon the efficacy profile of existing therapies.
According to our analysis, oral therapy remains the highest unmet need for both on-demand prophylactic use in HAE [live]. We aim to meet this need with PHA121, which is the convenient orally available novel
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
